Monday marks the last chance for investors to receive the next dividend payout from Zimmer Biomet Holdings (NYSE: ZBH ). What''s Happening The company announced on Wednesday that it would pay shareholders a quarterly dividend of 24 cents per share. On Tuesday, Zimmer Biomet Holdings will go ex-dividend, meaning the stock will trade lower to reflect that payout. … Full story available on Benzinga.com

Zimmer Biomet (ZBH) trended higher on Friday after Piper Sandler upgraded it arguing that the company has conservative guidance amid an upbeat joint market. Read the full story here.

https://www.investing.com/news/pro/piper-sandler-upgrades-zimmer-biomet-to-overweight-432SI-3027112

WARSAW, Ind., March 8, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2023. The cash…

DUBLIN , Feb. 23, 2023 /PRNewswire/ -- The "Global Knee Braces Market (2022-2027) by Product, Application, Delivery Channel, Type, End User, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Knee Braces Market is estimated to be USD 2.08 Bn in 2022 and is expected to reach USD 2.84 Bn by 2027, growing at a CAGR of 6.4% Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks.

The Dental Barrier Membrane Bone Graft Market outlook looks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data. The

Major players in the handheld surgical devices market are B. Braun Melsungen AG, Medtronic, Smith & Nephew, Johnson & Johnson Services Inc, Integra Life Sciences Corporation, Zimmer Biomet, CooperSurgical Inc, Becton, Dickinson and Company, and Moria. Major players in the handheld surgical devices market are B. Braun Melsungen AG, Medtronic, Smith & Nephew, Johnson & Johnson Services Inc, Integra Life Sciences Corporation, Zimmer Biomet, CooperSurgical Inc, Becton, Dickinson and Company, and Moria.

Major players in the joint reconstruction devices and equipment market are Smith & Nephew, Stryker, Zimmer Biomet, B. Braun Melsungen, Wright Medical Group, DePuy Synthes, Johnson & Johnson, Aesculap Implant Systems Inc, and Arthrex Inc. Major players in the joint reconstruction devices and equipment market are Smith & Nephew, Stryker, Zimmer Biomet, B. Braun Melsungen, Wright Medical Group, DePuy Synthes, Johnson & Johnson, Aesculap Implant Systems Inc, and Arthrex Inc.

Zimmer Biomet posted promising Q4 results, with revenue beats down the line and improved gross margin. Click here to read my current thoughts on ZBH stock.

Major players in the implantable biomaterials market are Evonik Industries AG, Royal DSM, Zimmer Biomet Holdings, Carpenter Technology Corporation, Collagen Matrix, Corbion, BASF SE, Invibio Ltd., and Celanese Corporation. Major players in the implantable biomaterials market are Evonik Industries AG, Royal DSM, Zimmer Biomet Holdings, Carpenter Technology Corporation, Collagen Matrix, Corbion, BASF SE, Invibio Ltd., and Celanese Corporation.

Related Stocks: GOOG , GOOGL , RRC , ZBH , TSLA ,

Related Stocks: EEM , MSFT , DIS , GILD , ZBH ,

Zimmer Biomet posted strong revenue growth in 4Q22 with organic growth of 10% and an earnings per share of $1.88. Click here to read more about ZBH stock.

https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-142-at-oppenheimer-432SI-2996112

https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-115-at-jefferies-432SI-2996102

https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-137-at-truist-securities-432SI-2996073

Zimmer Biomet Holdings Inc. (NYSE:NYSE:ZBH) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ETCompany ParticipantsBryan Hanson - President, Chief Executive OfficerSuketu Upadhyay…

WASHINGTON (dpa-AFX) - Zimmer Biomet Holdings Inc. (ZBH) said it expects adjusted earnings per share to be in the range $6.95 - $7.15 and revenue growth of 1.5% - 3.5% for fiscal year 2023. Analys…

Zimmer Biomet earnings beat by $0.05, revenue topped estimates

Zimmer Biomet press release (ZBH): Q4 Non-GAAP EPS of $1.88 beats by $0.05.Revenue of $1.83B (+3.4% Y/Y) beats by $70M.For FY2023, the company expects revenue growth of 1.5% to 3.5% vs

Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; adjusted1 diluted earnings per share from continuing operations were $1.88 Full-year net…

Zimmer Biomet (ZBH) is scheduled to announce Q4 earnings results on Friday, February 3rd, before market open.The consensus EPS Estimate is $1.83 (-6.2% Y/Y) and the consensus…

Zimmer Biomet Holdings (NYSE: ZBH ) is set to give its latest quarterly earnings report on Friday, 2023-02-03. Here''s what investors need to know before the announcement. Analysts estimate that Zimmer Biomet Holdings will report an earnings per share (EPS) of $1.82. Zimmer Biomet Holdings bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, … Full story available on Benzinga.com

Zimmer Biomet Holdings with ticker code (ZBH) now have 23 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 145 and 100 calculating the average target price we see 128.13. Given that the stocks previous close was at 125.5 this would indicate that there is a potential upside of 2.1%. The day 50 moving average is 123.36 and the 200 day MA is 115.21. The market cap for the company is $26,416m. Visit the company website at: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $26,970m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Related Stocks: AMT , ZBH , INVH , FAF , J ,

Zimmer Biomet Holdings found using ticker (ZBH) have now 23 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The target price ranges between 145 and 100 with the average target price sitting at 128.13. With the stocks previous close at 121.95 this now indicates there is a potential upside of 5.1%. The 50 day MA is 121.88 and the 200 day MA is 115.29. The company has a market cap of $26,041m. Company Website: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,360m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.